💨 Abstract
The World Health Organization (WHO) has prequalified Bavarian Nordic's mpox vaccine for adolescents aged 12-17, following EU approval. The decision aims to protect a vulnerable age group concerned by the global outbreak of mpox, a viral infection causing flu-like symptoms and skin lesions. Bavarian Nordic plans a clinical trial to assess the vaccine's safety in children aged 2-12.
Courtesy: theprint.in
Suggested
Sean 'Diddy' Combs jury decides on some counts; verdict not yet known
Jury reaches verdict on some counts at Sean 'Diddy' Combs' sex trafficking trial
US halts some missile shipments to Ukraine over low stockpiles, Politico reports
Venezuelan lawmakers declare UN human rights official Turk persona non grata
US halts some missile shipments to Ukraine over low stockpiles, sources say
Trump says US could reach trade deal with India, casts doubt on deal with Japan
Pro-Palestinian Georgetown student can remain free, US appeals court rules
Spain and World Bank in push for wider use of 'debt swaps'
Costa Rica's top court calls for President Chaves to stand trial on corruption charges
Israel's defence chief threatens to retaliate for Houthi missiles